Pheon Therapeutics, an antibody drug conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, has entered an exclusive licence agreement with Biocytogen Pharmaceuticals, a global biotech company focused on the discovery of novel antibody therapeutics. Under the terms of the agreement, Pheon will develop and commercialise an antibody developed using […]
